Israeli biotech firm Enzymotec has said it plans to enter the functional oils markets in Southeast Asia and Western Pacific following successful clinical trials of its CardiaBeat oil.
Go deeper with GlobalData
The company said both regions are suffering increasing incidences of obesity, heart disease, hypertension and diabetes as people move away from a traditional diet towards an increasingly westernised diet.
Enzymotec said recent clinical trials suggested that CardiaBeat is better at lowering the levels of cholesterol, triglycerides and oxidative stress in the body, compared to other oils and supplements already available.
